Raras
Buscar doenças, sintomas, genes...
Leucoencefalite multifocal progressiva
ORPHA:217260CID-10 · A81.2CID-11 · 8A45.02DOENÇA RARA

A leucoencefalopatia multifocal progressiva (LMP) é um distúrbio neurológico que danifica a mielina que cobre e protege os nervos na substância branca do cérebro. É causada pelo vírus JC (JCV). Aos 10 anos, a maioria das pessoas foi infectada com este vírus, mas ele raramente causa sintomas, a menos que o sistema imunológico fique gravemente enfraquecido. A doença ocorre, raramente, em pacientes transplantados de órgãos; pessoas em tratamento crônico com corticosteroides ou terapia imunossupressora; e indivíduos com câncer, como doença de Hodgkins, linfoma e sarcoidose. A LMP é mais comum entre indivíduos com síndrome da imunodeficiência adquirida (AIDS).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A leucoencefalopatia multifocal progressiva (LMP) é um distúrbio neurológico que danifica a mielina que cobre e protege os nervos na substância branca do cérebro. É causada pelo vírus JC (JCV). Aos 10 anos, a maioria das pessoas foi infectada com este vírus, mas ele raramente causa sintomas, a menos que o sistema imunológico fique gravemente enfraquecido. A doença ocorre, raramente, em pacientes transplantados de órgãos; pessoas em tratamento crônico com corticosteroides ou terapia imunossupressora; e indivíduos com câncer, como doença de Hodgkins, linfoma e sarcoidose. A LMP é mais comum entre indivíduos com síndrome da imunodeficiência adquirida (AIDS).

Pesquisas ativas
6 ensaios
30 total registrados no ClinicalTrials.gov
Publicações científicas
3.867 artigos
Último publicado: 2026

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: A81.2
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
8 sintomas
👁️
Olhos
3 sintomas
💪
Músculos
1 sintomas
🛡️
Imunológico
1 sintomas
🩸
Sangue
1 sintomas

+ 21 sintomas em outras categorias

Características mais comuns

90%prev.
Anormalidade do líquido cefalorraquidiano
Muito frequente (99-80%)
90%prev.
Morfologia anormal da oligodendroglia
Muito frequente (99-80%)
90%prev.
Anormalidade do sistema nervoso
Muito frequente (99-80%)
90%prev.
Proporção anormal de células T CD4
Muito frequente (99-80%)
90%prev.
Morfologia anormal do astrócito
Muito frequente (99-80%)
90%prev.
Déficit motor funcional
Muito frequente (99-80%)
35sintomas
Muito frequente (8)
Frequente (12)
Ocasional (11)
Muito raro (4)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 35 características clínicas mais associadas, ordenadas por frequência.

Anormalidade do líquido cefalorraquidianoAbnormality of the cerebrospinal fluid
Muito frequente (99-80%)90%
Morfologia anormal da oligodendrogliaAbnormality of the oligodendroglia
Muito frequente (99-80%)90%
Anormalidade do sistema nervosoAbnormality of the nervous system
Muito frequente (99-80%)90%
Proporção anormal de células T CD4Abnormal proportion of CD4 T cells
Muito frequente (99-80%)90%
Morfologia anormal do astrócitoAbnormal astrocyte morphology
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico3.867PubMed
Últimos 10 anos200publicações
Pico2025117 papers
Linha do tempo
2026Hoje · 2026🧪 1987Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
2Fase 26
1Fase 13
·Pré-clínico10
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Leucoencefalite multifocal progressiva

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

4 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

30 ensaios clínicos encontrados, 6 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
1.577 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 1.577

#1

[A case of cerebellar-limited HIV-associated progressive multifocal leukoencephalopathy diagnosed with the aid of the shrimp sign].

Rinsho shinkeigaku = Clinical neurology2026 Mar 11

A 43-year-old man presented with dizziness and slurred speech. A brain MRI with diffusion-weighted imaging and fluid-attenuated inversion recovery imaging revealed an abnormally high signal in the white matter of the left cerebellar hemisphere sparing the dentate nucleus, consistent with the characteristic "shrimp sign". Pathological findings from brain ‍biopsy were non-specific, however, JC virus-DNA was detected in the cerebrospinal fluid and anti-human immunodeficiency virus (HIV) antibodies were positive in the serum, leading to a diagnosis of HIV-associated progressive multifocal leukoencephalopathy (PML) limited to the cerebellum. Antiretroviral therapy was initiated, resulting in a favorable clinical course. The shrimp sign is highly specific to cerebellar PML and may facilitate an early diagnosis.

#2

Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments: A Multicenter Cohort Study.

Neurology(R) neuroimmunology &amp; neuroinflammation2026 May

JC virus (JCV) reactivation causing progressive multifocal leukoencephalopathy (PML) is a complication in patients with multiple sclerosis (MS) treated with disease-modifying therapies (DMTs). Although natalizumab (NTZ) is most frequently involved, PML also occurs less commonly with sphingosine-1-phosphate receptor modulators (S1P-RM), dimethyl fumarate (DMF), and ocrelizumab. This study aimed to identify factors predicting worse outcomes, focusing on the influence of PML-immune reconstitution inflammatory syndrome (PML-IRIS), plasma exchange (PlEx), corticosteroids, and DMT reintroduction. This retrospective multicenter cohort study analyzed patients with MS who had JCV-associated pathology (PML or granule cell neuronopathy) from 42 centers (2009-2022). The primary outcome was disability at 12 months, measured by the modified Rankin Scale (mRS). Multivariable analyses identified predictors of poor outcomes, PML-IRIS development, and recurrent MS activity. Of 96 identified patients, 94 were analyzed. Most cases occurred under NTZ (77%), followed by S1P-RM (22%) and DMF (1%). Twelve-month survival was 91.5%, with a median mRS of 3 [IQR: 2-4]. Multivariable analysis showed that higher pre-PML disability (OR: 1.95 [95% CI 1.46-2.60], p < 0.001), elevated CSF JCV viral load (OR: 2.45 [95% CI 1.55-3.87], p < 0.001), and symptomatic presentation at onset (OR: 3.93 [95% CI 1.23-12.55], p = 0.021) were associated with worse outcomes. Conversely, PML-IRIS was associated with better outcomes (OR: 0.28 [95% CI 0.09-0.86], p = 0.025). PlEx and corticosteroid use had no negative effect. This study provides valuable insights into the management of iatrogenic PML in patients with MS. The findings may guide clinicians in making informed decisions, particularly regarding the use of PlEx, corticosteroids, and the management of PML-IRIS.

#3

BK polyomavirus-associated progressive multifocal leukoencephalopathy following mogamulizumab therapy for erythrodermic mycosis fungoides.

Frontiers in cellular and infection microbiology2026

BK polyomavirus (BKPyV) is a ubiquitous human pathogen that typically causes nephropathy and hemorrhagic cystitis in immunocompromised patients. Although BKPyV shares close genetic and structural similarity with JC polyomavirus (JCPyV), which is responsible for progressive multifocal leukoencephalopathy (PML), its neurotropic potential remains poorly characterized. Rare reports have suggested possible central nervous system (CNS) involvement under conditions of severe immune suppression. Here, we describe the first documented case of BKPyV-associated PML in a patient with erythrodermic mycosis fungoides treated with Mogamulizumab, a CCR4-targeting monoclonal antibody that profoundly alters immune surveillance. We describe a patient with erythrodermic mycosis fungoides and long-standing immunological frailty, who developed neurological symptoms during Mogamulizumab therapy. Brain MRI showed multifocal white matter lesions compatible with PML. BKPyV DNA was detected in plasma, urine, and cerebrospinal fluid (CSF), while JCPyV DNA was absent. Serological testing showed high anti-BKPyV and anti-JCPyV IgG levels in plasma, indicating prior exposure to both viruses, while antibodies were undetectable in CSF, consistent with lack of intrathecal synthesis. This compartmental dissociation between plasma and CSF, together with the detection of BKPyV DNA and the absence of JCPyV DNA in CSF, supports BKPyV as the etiological neurotropic agent responsible for leukoencephalopathy. Sequencing of the VP1 and NCCR regions revealed compartment-specific nucleotide and amino acid variants, including non-conservative substitutions in the CSF isolate, suggesting intra-host viral heterogeneity. Compartment-specific sequence variability of viral protein 1 (VP1) and structural rearrangements of the non-coding control region (NCCR), particularly the loss of the Q and R block in CSF-derived isolates, underscore intra-host heterogeneity of BKV and may contribute to its adaptation and neurotropic potential. This is the first documented case of BKPyV-associated PML in a Mogamulizumab-treated patient. These findings highlight intra-host heterogeneity at the protein level, possibly reflecting compartment-specific viral evolution, and underscore the need for vigilant BKPyV and JCPyV monitoring during Mogamulizumab treatment.

#4

Practical Management of Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Inflammatory Syndrome.

Neurology. Clinical practice2026 Apr

The aim of this narrative review was to provide treating physicians with practical guidance on the management of progressive multifocal leukoencephalopathy (PML), offering a rational, evidence-informed approach to diagnosis and treatment based on published literature and the authors' collective clinical experience. The management of PML requires precise characterization of disease status at presentation and throughout follow-up. We begin by outlining the clinical scenarios in which PML should be suspected, emphasizing that disease presentation is shaped by the strength and quality of the host's antiviral immune response. We then detail the evaluation of patients at the time of diagnosis and during follow-up, with particular attention to defining whether PML is presenting in its classic form, with inflammatory features, or in the context of immune reconstitution inflammatory syndrome. This assessment should incorporate prognostic markers to evaluate the potential for immune recovery and virologic control. We further summarize the current standard of care and identify clinical contexts in which experimental immunotherapeutic interventions to facilitate restoration of JC virus-specific immune functions may be considered, emphasizing the importance of individualized, risk-benefit-based decision making. Notably, such experimental immunotherapies are likely unnecessary and may even be harmful, once immune reconstitution has already been achieved and virologic control is evident. Finally, we address the management of inflammation in PML, underscoring that not all inflammatory presentations warrant corticosteroid therapy. The management of PML remains a significant clinical challenge. Standardizing assessment protocols across centers may enhance data quality and comparability and facilitate future collaborative and data-sharing efforts.

#5

Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy using spontaneous reports: A 20-year signal detection study based on the FAERS database.

PloS one2026

Progressive multifocal leukoencephalopathy (PML) is a rare, often fatal demyelinating disease caused by JC virus reactivation in immunocompromised patients. With the increasing use of immunosuppressants and biologics, PML reporting in non-HIV populations is rising. This study aimed to evaluate drug-associated PML reporting signals using real-world pharmacovigilance data. We analyzed FAERS database from 2004Q1 to 2024Q4. We identified PML reports via MedDRA Terms and manual validation. Four algorithms (ROR, PRR, BCPNN, MGPS) were jointly applied, with drugs showing signals across all four defined as high-risk. 7,244 PML reports involving 298 drugs were identified; 72 drugs showed consistent signals, predominantly immunomodulators (e.g., natalizumab, rituximab), antineoplastics, and biologics. High-risk indications included multiple sclerosis, lymphoma, autoimmune diseases, and organ transplantation. PML reporting increased substantially in non-HIV populations. Time-to -reporting varied widely (49-1343days). Over one-third of reports were associated with life-threatening outcomes or death. This analysis identified 72 drugs with consistent PML reporting signals. However, these findings represent statistical associations in spontaneous reports, not causal relationships or true incidence rates. Inherent limitations-including underreporting, incomplete medication histories, and lack of exposure denominators-require cautious interpretation. Prospective validation studies are essential to establish causality and quantify absolute risks.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC2.018 artigos no totalmostrando 198

2026

Revisiting the Intracranial Neurological Imaging Manifestations of Human Immunodeficiency Virus: Pictorial Review with a Pattern-Based Approach.

The Indian journal of radiology &amp; imaging
2026

[A case of cerebellar-limited HIV-associated progressive multifocal leukoencephalopathy diagnosed with the aid of the shrimp sign].

Rinsho shinkeigaku = Clinical neurology
2026

Progressive multifocal leukoencephalopathy as the initial manifestation of relapsed lymphoma: a case report.

Frontiers in oncology
2026

Neurological Infections in HIV: A Case-Based Review for Clinicians.

Le infezioni in medicina
2026

Progressive Multifocal Leukoencephalopathy in a Patient With Miliary Tuberculosis: Differential Diagnosis From Tuberculoma.

Journal of clinical neurology (Seoul, Korea)
2026

MicroRNA biomarkers for JC virus reactivation and progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients: a systematic review.

Journal of neurovirology
2026

Pembrolizumab-Responsive Cerebellar PML in Untreated Sarcoidosis: A Case Report.

Cerebellum (London, England)
2026

Progressive Multifocal Leukoencephalopathy (PML) in 2 Patients Treated With Elranatamab.

Clinical lymphoma, myeloma &amp; leukemia
2026

Progressive multifocal leukoencephalopathy with parkinsonism and bilateral basal ganglia lesions.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

Transcranial Doppler Pulsatility Index and MRI Findings in Meningoencephalitis: A Pilot Observational Retrospective Cohort Study in Critically Ill Patients.

Clinics and practice
2026

Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments: A Multicenter Cohort Study.

Neurology(R) neuroimmunology &amp; neuroinflammation
2026

BK polyomavirus-associated progressive multifocal leukoencephalopathy following mogamulizumab therapy for erythrodermic mycosis fungoides.

Frontiers in cellular and infection microbiology
2026

Hepatic Manifestations of STAT1 Gain-of-Function Variants.

The journal of allergy and clinical immunology. In practice
2026

Late-onset progressive multifocal leukoencephalopathy after teclistamab in multiple myeloma: extending the timeline of infectious risk.

Haematologica
2026

Progressive Multifocal Leukoencephalopathy in Patients with HIV-Case Series from Northeastern Romania.

Journal of clinical medicine
2026

Practical Management of Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Inflammatory Syndrome.

Neurology. Clinical practice
2026

[Progressive multifocal leukoencephalopathy in HIV-negative patients for general practitioners].

Revue medicale suisse
2026

HIV-associated neurological infections in a Brazilian tertiary care center: clinical-epidemiological features and predictors of in-hospital mortality.

Revista do Instituto de Medicina Tropical de Sao Paulo
2026

Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy using spontaneous reports: A 20-year signal detection study based on the FAERS database.

PloS one
2026

Biopsy-Confirmed Progressive Multifocal Leukoencephalopathy During Epcoritamab Therapy Despite Negative CSF JC Virus PCR: A Case Report.

Acta neurologica Belgica
2026

A multicenter, retrospective study in patients with multiple sclerosis treated with natalizumab in a real-world setting in Japan: The REFIND study.

Multiple sclerosis and related disorders
2026

Progressive multifocal leukoencephalopathy associated with elranatamab therapy in relapsed/refractory multiple myeloma.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
2026

JC polyomavirus (JCV, HPyV2) seropositivity prevalence in healthy subjects: Systematic review and meta-analysis.

PloS one
2026

Inter-assay variability in anti-JC virus testing for natalizumab: A Spanish cohort.

Multiple sclerosis and related disorders
2026

BK and JC polyomavirus co-infection resulting in polyomavirus nephropathy and progressive multifocal leukoencephalopathy at the same time, a case report.

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
2026

Virus-Specific T Cells and Response to Checkpoint Inhibitors in Progressive Multifocal Leukoencephalopathy.

JAMA neurology
2026

Diagnosing progressive multifocal leukoencephalopathy: clinical features, neuroimaging findings, confirmatory testing and proposed diagnostic algorithm.

Practical neurology
2025

Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy: roles of underlying diseases and immunomodulatory therapies in FAERS.

Frontiers in immunology
2026

Investigating the Frequency and Outcome of Central Vein Sign and Paramagnetic Rim Lesions in Children With MOGAD.

Neurology
2025

PD-1 regulates CD4+ T cell-mediated CD8+ T cell responses in the brain to balance viral control and neuroinflammation.

Research square
2025

Hashimoto's Encephalopathy in a Critically Ill Patient With Polysubstance Use: A Diagnostic Challenge.

AACE endocrinology and diabetes
2025

A report of progressive multifocal leukoencephalopathy during adjuvant abemaciclib for breast cancer.

Journal of neurovirology
2025

Ethical and Clinical Considerations in the Workup of HIV-Associated Neurocognitive Decline.

Cureus
2025

Progressive Multifocal Leukoencephalopathy Mimicking Stroke in a Patient With Newly Diagnosed HIV: A Case Report.

Cureus
2025

Deltoid Administration of LAI-ART: Pharmacokinetic Implications When the Gluteal Site Is Not Feasible.

Le infezioni in medicina
2025

Progressive Multifocal Leukoencephalopathy after Administration of Front-Line Obinutuzumab and Venetoclax in a Patient with Chronic Lymphocytic Leukemia: Case Report.

Case reports in oncology
2025

Diagnostic difficulties in progressive multifocal leukoencephalopathy: a case report.

Folia neuropathologica
2025

A real-world safety analysis of infection-related adverse events associated with belimumab, rituximab, and TNF inhibitors using the FAERS database.

Scientific reports
2026

Phenotypic spectrum, etiology and outcomes of infection-related movement disorders: An observational cohort study.

Parkinsonism &amp; related disorders
2025

Molecular characterization of JC virus in progressive multifocal leukoencephalopathy cases from India.

Scientific reports
2026

Successful Treatment of Progressive Multifocal Leukoencephalopathy With Tenofovir Alafenamide Fumarate.

Neurology(R) neuroimmunology &amp; neuroinflammation
2025

Long-term progressive multifocal leukoencephalopathy risk stratification in multiple sclerosis patients treated with natalizumab with positive John Cunningham virus index.

Neurologia i neurochirurgia polska
2026

Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age.

Inflammatory bowel diseases
2025

JC polyomavirus neuroinvasion across the blood-brain barrier: Current understanding and emerging perspectives.

Tumour virus research
2025

Progressive Multifocal Leukoencephalopathy in a Young Male With Concurrent Neurosyphilis and HIV Infection: A Case Report.

Journal of the International Association of Providers of AIDS Care
2025

Comparative evaluation of STRATIFY JCV™ and IMMUNOWELL™ assays for anti-JCV antibody detection in natalizumab-treated RRMS patients.

Therapeutic advances in neurological disorders
2025

A Case of Cerebellar-Onset Progressive Multifocal Leukoencephalopathy (PML) Associated with Hepatitis B-related Liver Cirrhosis.

Internal medicine (Tokyo, Japan)
2025

Progressive multifocal leukoencephalopathy in a young adult with DOCK8 deficiency: a case of JC virus reactivation in primary immunodeficiency.

Journal of neurovirology
2025

Progressive Multifocal Leukoencephalopathy as the Initial Presentation of Undiagnosed HIV Infection: A Case Report.

Cureus
2026

Paramagnetic Rim Lesions in Pediatric Multiple Sclerosis and Their Association With Brain Tissue Atrophy.

Neurology(R) neuroimmunology &amp; neuroinflammation
2025

Hypogammaglobulinemia and infection rates in patients with multiple sclerosis treated with ocrelizumab for up to six years: A real-world single-center study.

Multiple sclerosis journal - experimental, translational and clinical
2025

CAR T cells for multiple sclerosis: Engineering T cells to disrupt chronic B cell-driven neuroinflammation.

Multiple sclerosis and related disorders
2025

Comparison of clinical, radiological and outcome parameters in patients with progressive multifocal leukoencephalopathy (PML) with and without HIV infection: a cohort study.

Journal of neurovirology
2025

JC Virus Agnogene Regulates Histone-Modifying Enzymes via PML-NBs: Transcriptomics in VLP-Expressing Cells.

Viruses
2025

A narrative review on the safety of glatiramer acetate in multiple sclerosis: focus on Europe.

Therapeutic advances in chronic disease
2025

Paradoxical Progressive Multifocal Leukoencephalopathy With Immune Reconstitution Inflammatory Syndrome in a Patient With AIDS: A Case Report.

Cureus
2025

JC virus PCR assay reporting for PML: promises, perils, and pitfalls.

Journal of neurology
2025

Progressive multifocal leukoencephalopathy recrudescence in an autoimmune hepatitis flare.

BMJ case reports
2025

Long-Term Safety of Vedolizumab in Patients With Ulcerative Colitis/Crohn's Disease: A Prospective Observational Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2025

Cortical lesions are common in a longitudinal progressive multifocal leukoencephalopathy cohort.

Brain communications
2026

Progressive multifocal leukoencephalopathy and BK virus-nephropathy with bispecific antibody therapy in multiple myeloma.

Haematologica
2025

A Case Report of Progressive Multifocal Leukoencephalopathy (PML) in an Immunocompetent Patient.

Cureus
2025

Suboptimal dose of approved disease modifying therapies in management of patients with multiple sclerosis: A systematic review.

Multiple sclerosis and related disorders
2025

IRIS without PML in MS patients - a case report of IRIS after past alemtuzumab therapy with subsequent oral cladribine treatment and review of the literature.

Annals of agricultural and environmental medicine : AAEM
2025

Successful treatment of HIV-related progressive multifocal leukoencephalopathy and immunological reconstitution inflammatory syndrome with intravenous human immunoglobulin: a case report.

AIDS research and therapy
2026

Annual 12-Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition.

Annals of clinical and translational neurology
2025

CRISPR and Myelin regeneration: a systematic review of applications in demyelinating CNS Disorders, with a focus on MS.

Regenerative medicine
2025

Distinguishing Progressive Multifocal Leukoencephalopathy From Cerebral Toxoplasmosis in HIV: A Case Report.

Cureus
2025

Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook.

Therapeutic advances in neurological disorders
2025

Live long and persist: polyomavirus immune evasion in the brain and kidney.

Future virology
2025

The presence of human polyomavirus JC (JCPyV) in pediatric brain tumors: a plausible trigger in Wnt/β-catenin pathway.

Journal of neurovirology
2025

Progressive multifocal leukoencephalopathy as a rare first manifestation of AIDS: case report.

Postepy psychiatrii neurologii
2025

Late-Onset Combined Immunodeficiency presenting with Progressive Multifocal Leukoencephalopathy and associated Immune Reconstitution Inflammatory Syndrome.

Le infezioni in medicina
2025

Changing clinical and laboratory characteristics of Progressive Multifocal Leukoencephalopathy: a retrospective national cohort study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
2026

Classic Magnetic Resonance Imaging Features Unmask Progressive Multifocal Leukoencephalopathy in Rituximab-Treated Neuropsychiatric Systemic Lupus Erythematosus.

The Journal of rheumatology
2025

Natalizumab-Associated Progressive Multifocal Leukoencephalopathy After Natalizumab Extended Interval Dosing Therapy in Japan.

Neurology(R) neuroimmunology &amp; neuroinflammation
2025

Therapeutic potential of flavonols in the treatment of JCPyV.

Microbiology spectrum
2025

JCV-specific cell-based assays for PML risk assessment in lupus and multiple sclerosis patients with and without natalizumab.

Frontiers in neurology
2025

BKPyV causing meningoencephalitis in HIV/AIDS patients in Argentina.

Diagnostic microbiology and infectious disease
2025

Neurovascular pericytes are susceptible to infection by JC polyomavirus.

Journal of virology
2025

Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database.

Frontiers in pharmacology
2025

Identification of Novel Wraparound Transcripts in JC Polyomavirus.

Journal of medical virology
2025

John Cunningham (JC) Virus Encephalitis Without Progressive Multifocal Leukoencephalopathy in a Stem Cell Transplant Patient: A Case Report and Literature Review.

Cureus
2026

Progressive Multifocal Leukoencephalopathy Initially Considered as Central Nervous System Involvement of Post-Transplant Lymphoproliferative Disorder: The Critical Role of Contrast Enhancement on Magnetic Resonance Imaging.

Internal medicine (Tokyo, Japan)
2025

Genetics of progressive multifocal leukoencephalopathy: update on case reports with an inborn error of immunity and risk variants found in drug-linked cases.

Frontiers in neurology
2025

Delayed access and adherence are real-world challenges that compromises effectiveness of natalizumab in multiple sclerosis.

Multiple sclerosis and related disorders
2025

Adoptive JC Virus-Specific T Lymphocytes for the Treatment of Progressive Multifocal Leukoencephalopathy: Experience from Two Italian Centers.

Viruses
2025

JC Polyomavirus Infection: A Narrative Review.

Infectious diseases and therapy
2025

[An autopsy case of non-drug related progressive multifocal leukoencephalopathy in a background of rheumatoid arthritis].

Rinsho shinkeigaku = Clinical neurology
2025

[A case of treatment-related leukoencephalopathy during combination therapy with daratumumab, lenalidomide, and low-dose dexamethasone for multiple myeloma].

Rinsho shinkeigaku = Clinical neurology
2025

First detection of JC polyomavirus in vaginal secretions from nonpregnant women: Exploring sexual transmission as a potential route of infection.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
2025

Overview of MRI findings in progressive multifocal leukoencephalopathy.

Japanese journal of radiology
2025

JC Virus-Related Retinopathy.

JAMA ophthalmology
2025

[Progressive multifocal leukoencephalopathy: an important differential diagnosis of a white matter lesion in immunocompromised patients].

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin
2025

The boundaries between PML and PML-IRIS: difficult to define, pathology may predict.

Frontiers in cellular and infection microbiology
2025

Natalizumab-associated progressive multifocal leukoencephalopathy.

Frontiers in neurology
2025

Exploring the effectiveness of cytarabine in people living with HIV with progressive multifocal leukoencephalopathy: a retrospective cohort study in Chongqing, China.

Journal of neuroimmunology
2025

Progressive Multifocal Leukoencephalopathy in Chimeric Antigen Receptor T-Cell Therapy Recipients: A Case Study.

Journal of the advanced practitioner in oncology
2025

Progressive multifocal leukoencephalopathy secondary to idiopathic CD4 lymphocytopenia with balanced CD4/CD8 inflammation significantly improved after treatment with mirtazapine and mefloquine.

Journal of the neurological sciences
2025

CXCR4 and CXCR6 dually limit T cell entry into the polyomavirus-infected brain.

Journal of neuroinflammation
2025

Cerebellum-Predominant Progressive Multifocal Leukoencephalopathy: An Under-recognized Cause of Cerebellar Syndrome among People with Human Immunodeficiency Virus Infection.

Neurology India
2025

Efficacy of filgrastim therapy for patients with progressive multifocal leukoencephalopathy: Two case reports.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
2025

Is Cauda Equina Involvement Related to BK Virus in Patients with Combined Immunodeficiency?

The Indian journal of radiology &amp; imaging
2025

A comparison of JC virus assay performance provided with originator and biosimilar natalizumab.

Multiple sclerosis (Houndmills, Basingstoke, England)
2025

Beyond the switch to the biosimilar of natalizumab: What is the impact of changing the JCV test?

Multiple sclerosis (Houndmills, Basingstoke, England)
2025

CRISPR antiviral inhibits neurotrophic JC polyomavirus in 2D and 3D culture models through dual-gRNA excision by SaCas9.

Molecular therapy. Nucleic acids
2025

A Systematic Review of BK and JC Polyomaviruses in Asia: Molecular Insights and Prevalence.

Reviews in medical virology
2025

Effectiveness of anti-CD20 therapies following natalizumab discontinuation: insights from a cohort study.

Multiple sclerosis and related disorders
2025

Rapid onset of neurological symptoms in an HIV-positive patient with progressive multifocal leukoencephalopathy: a case report.

Annals of medicine and surgery (2012)
2025

Approach to JCV testing with natalizumab biosimilar: a UK consensus statement.

Multiple sclerosis and related disorders
2025

TSPO PET in multiple sclerosis: Emerging insights into pathophysiology, prognosis, and treatment monitoring.

Multiple sclerosis and related disorders
2025

Progressive Multifocal Leukoencephalopathy (PML) after hematopoietic cell transplantation (HCT): a retrospective study of Infectious Diseases Working Party (IDWP) of the EBMT.

Bone marrow transplantation
2025

Changes in circulating pro-inflammatory lymphocytes and cortical excitability with extended-interval natalizumab dosing in multiple sclerosis.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Disease Course in Patients Switched from Natalizumab to Alemtuzumab: An Italian Multicenter, Prospective, Observational Study.

Neurology and therapy
2025

Histomorphological variations in progressive multifocal leukoencephalopathy correlated with JCV replication in brain lesions: insights from 91 patients.

Acta neuropathologica communications
2025

Comparative Efficacy and Safety of Extended Versus Standard Interval Dosing of Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients: A Multicenter Analysis.

CNS neuroscience &amp; therapeutics
2025

I saw the "Milky Way sign" and the "Barbell sign" in the same patient.

Clinical imaging
2025

The role of the immune system in progressive multifocal leukoencephalopathy: a comparative analysis of two cases following autologous and allogeneic hematopoietic stem cell transplantation.

Annals of hematology
2025

Case Report: Neurofilament light chain in the follow up of progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with ocrelizumab.

Frontiers in pharmacology
2025

Early diagnosis of progressive multifocal leukoencephalopathy in untreated HIV infection via ultrasensitive PCR testing for JC virus: A case report.

IDCases
2025

Selective IgM Hypogammaglobulinemia and Multiple Sclerosis Treated with Natalizumab and Ofatumumab: A Case Report.

Journal of personalized medicine
2025

Progressive Multifocal Leukoencephalopathy in Kidney Transplant Recipients: A Retrospective Multicenter Nationwide Case Series.

American journal of kidney diseases : the official journal of the National Kidney Foundation
2025

Progressive multifocal leukoencephalopathy during 4 years of Palbociclib for advanced breast cancer with a history of follicular lymphoma patient.

Journal of neurovirology
2025

Navigating the uncharted-Progressive multifocal leukoencephalopathy in a child with NMOSD treated with rituximab.

Multiple sclerosis (Houndmills, Basingstoke, England)
2025

A first report of progressive multifocal leukoencephalopathy in childhood-onset NMOSD.

Multiple sclerosis (Houndmills, Basingstoke, England)
2025

JC Polyomavirus-Associated Nephropathy Case Report: Clinical and Laboratory Learning.

British journal of biomedical science
2025

Comparing STRATIFY JCV™ DxSelect™ and IMMUNOWELL™ JCV Tests in RRMS to Assess PML Risk.

Current neuropharmacology
2025

Trends in the real-world management of patients with active relapsing-remitting multiple sclerosis treated with natalizumab (TYSABRI®) in France: An analysis of the PMSI database over five years (2019-2023).

Revue neurologique
2025

Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis.

JAMA neurology
2025

Polyomaviruses After Allogeneic Hematopoietic Stem Cell Transplantation.

Viruses
2025

Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis.

Journal of neurology, neurosurgery, and psychiatry
2025

The microvascular endothelium of the blood-brain barrier is highly restrictive to JC Polyomavirus neuroinvasion.

Microbiology spectrum
2025

Progressive multifocal leukoencephalopathy in rheumatoid arthritis and biological therapies: a case report and review of the literature.

Journal of medical case reports
2025

MRI Shrimp Sign and Parietooccipital Lesion in Progressive Multifocal Leukoencephalopathy.

Cerebellum (London, England)
2025

Prolonged survival in HIV-associated Progressive Multifocal Leukoencephalopathy treated with Pembrolizumab: a case series on treatment and long-term follow-up.

Journal of neurovirology
2025

LymphoTEC: a Retrospective Real-World Study on Lymphocyte Reconstitution After Lymphopenia in Patients with Multiple Sclerosis Treated with Dimethyl Fumarate in France.

Advances in therapy
2025

Portable ultra-low-field MRI for progressive multifocal leukoencephalopathy: Case studies, sensitivity, and potential applications.

Journal of neurology
2025

[Progressive multifocal leukoencephalopathy developed 3 years after related HLA-haploidentical peripheral blood stem cell transplantation].

[Rinsho ketsueki] The Japanese journal of clinical hematology
2025

Sintilimab for treating progressive multifocal leukoencephalopathy caused by human polyomavirus 2 virus infection following allogeneic hematopoietic cell transplantation: a case report.

Hematology (Amsterdam, Netherlands)
2025

Progressive Multifocal Leukoencephalopathy in a Young Medication-Noncompliant HIV Patient: A Case Report and Literature Review.

Cureus
2025

Effectiveness of 6-week dosing of Natalizumab versus continued 4-week treatment for Multiple Sclerosis: An observational registry-based study.

Multiple sclerosis and related disorders
2025

John Cunningham virus as cause of progressive multifocal leukoencephalopathy.

Neurologia i neurochirurgia polska
2025

An MRI assessment of mechanisms underlying lesion growth and shrinkage in multiple sclerosis.

Annals of clinical and translational neurology
2024

Evaluating Neural Network Performance in Predicting Disease Status and Tissue Source of JC Polyomavirus from Patient Isolates Based on the Hypervariable Region of the Viral Genome.

Viruses
2025

Cerebral Microbleeds and Amyloid Pathology Estimates From the Amyloid Biomarker Study.

JAMA network open
2025

Mixed nontuberculous mycobacteria in an immunocompromised patient with probable progressive multifocal leukoencephalopathy.

IJID regions
2025

Diagnostic Insighhts Into JC Virus-Infected Glial Cells: Intraoperative Cytopathological Analysis of Dot-Shaped Inclusions Associated With PML-NBs.

Cytopathology : official journal of the British Society for Clinical Cytology
2024

Performance of Ultrasensitive Polymerase Chain Reaction Testing for JC Polyomavirus in Cerebrospinal Fluid Compared with Pathological Diagnosis of Progressive Multifocal Leukoencephalopathy.

Viruses
2024

Analysis of Immunological Memory for John Cunningham Virus in a Mexican Population of Patients with Multiple Sclerosis Under Treatment.

Biomedicines
2025

Diagnosing progressive multifocal leukoencephalopathy: Positive predictive value of CSF JC virus quantitative PCR and importance of recognizing suggestive neuroimaging findings.

Journal of the neurological sciences
2025

Anti-JCV antibody index seroconversion in Turkish multiple sclerosis patients treated with natalizumab.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Progressive multifocal leukoencephalopathy, the role of the susceptibility-weighted imaging sequence in a case of immunosuppression of an initially unknown cause.

Encephalitis (Seoul, Korea)
2025

Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know.

Annals of emergency medicine
2025

Recent advances in discovery and functional analysis of the small proteins and microRNA expressed by polyomaviruses.

Virology
2024

"Pardon My Language": The Curious Case of a Bloody Sandwich and the John Cunningham Virus Reactivation in the Era of Immunomodulatory Drugs.

Cureus
2024

Antigen-Specific T Cell Receptor Discovery for Treating Progressive Multifocal Leukoencephalopathy.

bioRxiv : the preprint server for biology
2024

Real-World Effectiveness and Safety of Carotegrast Methyl in Japanese Patients with Moderately Active Ulcerative Colitis.

Inflammatory intestinal diseases
2024

A Case of Progressive Multifocal Leukoencephalopathy Caused by Epcoritamab.

Cureus
2024

Progressive multifocal leukoencephalopathy associated with sphingosine-1-phosphate receptor modulators: A large case series.

Multiple sclerosis and related disorders
2024

Brain biopsy and pathological diagnosis for drug-associated progressive multifocal leukoencephalopathy (PML) with inflammatory reactions.

Pathology international
2024

Transient biopsy-proven progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS) in an elderly woman without known immunodeficiency: a case report.

BMC neurology
2024

Elevation of serum neurofilament light-chain levels disclose possible occult progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient receiving ozanimod: a case report.

Frontiers in immunology
2024

Proteome profiling of polyomavirus nuclear replication centers using iPOND.

Journal of virology
2024

Stroke Mimics: A Case of John Cunningham Virus-Induced Progressive Multifocal Leukoencephalopathy.

Cureus
2024

Case report: Progressive multifocal leukoencephalopathy co-occurring with neurosarcoidosis: early brain biopsy and appropriate therapy for PML resulted in a favorable prognosis.

Frontiers in immunology
2024

GPCR Inhibitors Have Antiviral Properties against JC Polyomavirus Infection.

Viruses
2024

Ideomotor Apraxia and "Milky Way" Sign in Progressive Multifocal Leukoencephalopathy.

Neurology
2024

Identification of JC polyomavirus in upper respiratory samples from Portuguese children.

Heliyon
2024

Combination of low-dose, long-term immunoglobulin and mirtazapine is effective in progressive multifocal leukoencephalopathy caused by JC virus infection.

BMC neurology
2024

Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.

Neurology(R) neuroimmunology &amp; neuroinflammation
2024

Deciphering Proteomic Expression in Inflammatory Disorders: A Mass Spectrometry Exploration Comparing Infectious, Noninfectious, and Traumatic Brain Injuries in Human Cerebrospinal Fluid.

Neurotrauma reports
2024

Directly Isolated Allogeneic Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy.

JAMA neurology
2024

Progressive Multifocal Leukoencephalopathy in a Patient With Cirrhosis and Hepatocellular Carcinoma.

The Neurohospitalist
2024

Progressive multifocal leukoencephalopathy in systemic lupus erythematosus treated with pembrolizumab.

BMJ case reports
2024

HIV-Associated Neurocognitive Disorder and CNS Viral Escape: A Case Report.

Cureus
2024

[Progressive multifocal leukoencephalopathy in HIV-positive individuals].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2024

Progressive Multifocal Leukoencephalopathy confined to the posterior fossa as the presenting manifestation of HIV in a paediatric patient.

IDCases
2024

Progressive multifocal leukoencephalopathy after CAR-T cell therapy.

Bone marrow transplantation
2024

Advances in virus-specific T-cell therapy for polyomavirus infections: A comprehensive review.

International journal of antimicrobial agents
2024

Efficacy and Safety of Bendamustine-Rituximab as Frontline Therapy for Indolent Non-Hodgkin Lymphoma: A Real-World, Single-Center, Retrospective Study.

Cureus
2024

A rare case of progressive multifocal leukoencephalopathy.

Radiology case reports
2024

Safety of high efficacy therapies in older people with Multiple Sclerosis: A real-world evidence study.

Multiple sclerosis and related disorders
2024

Neurosarcoidosis as a rapidly progressive dementia associated with normal pressure hydrocephalus.

Medicina
2024

Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: A Multicenter Cohort Study.

Neurology(R) neuroimmunology &amp; neuroinflammation
2024

Progressive Multifocal Leukoencephalopathy in Myasthenia Gravis With Selective Hypogammaglobulinemia.

Journal of clinical neuromuscular disease
2024

Unveiling the Enigma: John Cunningham Virus-Associated Progressive Multifocal Leukoencephalopathy in an Immunocompetent Individual.

Cureus
2024

Unusual demyelinating disease in a patient with HIV infection.

Journal of neurovirology
2024

Progressive multifocal leukoencephalopathy in sarcoidosis successfully treated with pembrolizumab.

Journal of neurovirology
2024

[Case report and literature review of AIDS-related progressive multifocal leukoencephalopathy diagnosed in a psychiatric department].

Orvosi hetilap
2024

"One a penny, two a penny", I saw the hot cross bun sign".

Clinical imaging
2024

Advances in diffuse glioma assessment: preoperative and postoperative applications of chemical exchange saturation transfer.

Frontiers in neuroscience
2024

JC virus spread is potentiated by glial replication and demyelination-linked glial proliferation.

Brain : a journal of neurology
2024

JCV granule cell neuronopathy: A rare case manifestation.

Clinical neuropathology
2024

Frequent detection of IFN-gamma -producing memory effector and effector T cells in patients with progressive multifocal leukoencephalopathy.

Frontiers in immunology
2024

Safety and effectiveness of disease-modifying therapies after switching from natalizumab.

Multiple sclerosis (Houndmills, Basingstoke, England)
2024

Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.

Blood advances
2024

Atypical Presentation of a Patient With Progressive Multifocal Leukoencephalopathy.

Cureus
2024

Ocrelizumab-induced organizing pneumonia in multiple sclerosis: case report and literature review.

Archive of clinical cases
Ver todos os 2.018 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Leucoencefalite multifocal progressiva.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Leucoencefalite multifocal progressiva

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. [A case of cerebellar-limited HIV-associated progressive multifocal leukoencephalopathy diagnosed with the aid of the shrimp sign].
    Rinsho shinkeigaku = Clinical neurology· 2026· PMID 41813188mais citado
  2. Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments: A Multicenter Cohort Study.
    Neurology(R) neuroimmunology &amp; neuroinflammation· 2026· PMID 41719500mais citado
  3. BK polyomavirus-associated progressive multifocal leukoencephalopathy following mogamulizumab therapy for erythrodermic mycosis fungoides.
    Frontiers in cellular and infection microbiology· 2026· PMID 41716458mais citado
  4. Practical Management of Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Inflammatory Syndrome.
    Neurology. Clinical practice· 2026· PMID 41669757mais citado
  5. Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy using spontaneous reports: A 20-year signal detection study based on the FAERS database.
    PloS one· 2026· PMID 41632714mais citado
  6. Progressive multifocal leukoencephalopathy - a diagnostic guide for the clinical neurologist.
    Front Neurol· 2026· PMID 41988494recente
  7. Pembrolizumab Experience in a Patient with Progressive Multifocal Leukoencephalopathy Following Multiple Myeloma Treatment: A Case Report and Literature Review.
    Noro Psikiyatr Ars· 2026· PMID 41969960recente
  8. Progressive multifocal leukoencephalopathy associated with immune dysregulation.
    BMJ Case Rep· 2026· PMID 41962960recente
  9. Threshold-Dependent Discordance Between STRATIFY JCV™ and IMMUNOWELL™ Assays in Relapsing Multiple Sclerosis.
    Neurol Ther· 2026· PMID 41961241recente
  10. Progressive Multifocal Leukoencephalopathy: A Rare Cause of Altered Mentation.
    Cureus· 2026· PMID 41930052recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:217260(Orphanet)
  2. MONDO:0016318(MONDO)
  3. GARD:7468(GARD (NIH))
  4. Busca completa no PubMed(PubMed)
  5. Artigo Wikipedia(Wikipedia)
  6. Q704930(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Leucoencefalite multifocal progressiva
Compêndio · Raras BR

Leucoencefalite multifocal progressiva

ORPHA:217260 · MONDO:0016318
Prevalência
Unknown
Herança
Not applicable
CID-10
A81.2 · Leucoencefalopatia multifocal progressiva
CID-11
Ensaios
6 ativos
Início
All ages
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0023524
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades